The well-known pharmaceutical company was acquired 7.5 billion yuan, officially listed

Medical Network May 14 hearing from Hong Kong after the privatization, which is well-known pharmaceutical companies 7.5 billion acquisition, officially listedMay 12, East sound of shares announced, the securities referred to officially changed its name to "Elohim Pharmaceutical" - from today, Elohim Pharmaceutical cross-border takeover, backdoor listing formally completedsound the East shares the main business major changes, the transition intomanufacturing industry, the main business of pharmaceutical product development, production and salesStatistics show that before the East sound shares the main business of wells with submersible pumps, small submersible pumps, pump onshore development, production and sales, from today, the shares officially transformed into sound East pharmaceutical manufacturingAccording to announcement, the company agreed to the company's Chinese name from "Zhejiang East Tone Pump Co., Ltd." to "Elohim Pharmaceutical Group Co., Ltd.", the English name of "ZhejiangDoyinPumpIndustryCo., Ltd"is changed to" LuoxinPharmaceuticalsGroupStockCo., Ltd", the company securities referred to by the" East tone shares "to" Elohim medicine"2020 April 28, the company has made renewal of the Zhejiang Administration of the market "business license", the company name changed to "Elohim Pharmaceutical Group Co., Ltd." Major assets and issue sharesreasons for this change of tone from the East shares implemented in 2019 to buy assets matters, the acquisition of Shandong Elohim Pharmaceutical Group Co., Ltd99.654% of the sharesElohim Pharmaceutical is one of the few Hong Kong stocks after the recent successful privatization of delisting again in the A-share backdoor listing of cases2001, the original weight of the restructuring Pegasys pharmaceutical composition LUOXIN PHARMAIn December 2005, landing HKExboardBut from 2013 to 2015, because the desire higher activity motherboard market, but also to seek a higher valuation, Elohim Pharmaceutical turn on three occasions to submit an application to the HKEx board, but have been turned away in June 2017, only Elohim Pharmaceutical privatization of delisting way: in March 2017 received a privatization offer price of HK $ 17 / share, representing a proposed transaction before the offer day price premium of nearly 32% June of that year Elohim Pharmaceutical complete delisting, that time worth more than HK $ 10 billion Profitability Elohim Pharmaceutical industry has also been concern, 2016,2017, 2018, Elohim Pharmaceutical net profit attributable to equity holders were 4.26 billion yuan, 466 million yuan and 512 million yuan east sound Shares January 16th 2019, disclosed the evening performance, the company expects 2019 net profit attributable to 620 million yuan -6.5 billion, an increase of 456.82% - 483.77%, the soaring performance was mainly the company in December 2019 completed a major assets and issue shares to buy assets transfer will be registered into the assets and Connected Transaction and fulfilled set out the assets of the obligation to deliver, Elohim Pharmaceutical holding company to become child The company, its operating results included in the consolidation scope But in general, the East has a sound of its own shares on the relatively good profitability April 2016 listing of small plates, from the annual reports, the company's revenue continued to grow, and the mother of three-year normalized net profit of 1 million or more Why it decided to sell the shell? This may Elohim Pharmaceutical and performance commitments made related In the restructuring plan, the Elohim Pharmaceutical year 2019 to the 2020 annual net profit of the parent and non-normalized buckle year 2021 will be realized of not less than 550 million yuan, 650 million yuan and 7.5 billion yuan public information display, the first half of 2019 Elohim Pharmaceutical actual operating income of 39.3 billion yuan, accounting for 52% of the annual number of prediction; the first half of 2019 attributable to the actual implementation of Elohim Pharmaceutical net profit to equity holders of 300 million yuan, accounting for 55% of the full-year forecast Elohim Pharmaceutical future ability to complete the restructuring plan in the performance commitment, worthy of further follow-up attention bulletin previously disclosed, a total Luoxin New Drug Certificate 48, in a class of drugs RESEARCH 6, the main focus in the digestive, respiratory, a class of anti and other fields Among them, the highest proportion of R & D projects category for anti-tumor field According to wind data, the 2018 Elohim Pharmaceutical R & D staff 429 people, R & D investment accounted for 8.45% of revenue, were higher than the same period the industry average R & D personnel and the number of the same period the industry average R & D investment accounted for operating income proportion because of the continuing arrival of generic drugs to evaluate the agreement and new rules, health insurance funds cage for a bird's unstoppable trend, a growing number of innovative drugs which are covered, Chinese pharmaceutical companies have increased investment in innovation and R & D, to explore how the products mature, steady shift to innovative products Therefore, there is growing pharmaceutical companies innovative ability, in the capital markets will be more popular should be noted that, from the point of view product schedule, Elohim Pharmaceutical has over 90 projects in development, including 28 major products in development But in the case of research projects in the company's disclosure point of view, the company developed a new drug from commercialization is still some distance - a lot of the company's Class 1 innovative drugs are in preclinical or clinical one, to the future profitability of listed real, there are greater risks and uncertainties addition to innovative products, are also part of the company problem of decline in the market share pin product: Annual Pharmaceutical LUOXIN display, market position relative to the front of respiratory and digestive systems specialist drug use is the main revenue, showing a trend contribution to growth; at the same time, because the policy limit and other factors lead to anti-antibiotics growth is slowing down, the market share is declining challenges and opportunities, the Elohim Pharmaceutical got what they wanted through the backdoor listing into a higher valuation, more active A-share market, the future is complete commitment to performance, whether to implement the new growth, blue cypress race will continue to focus.